RxDoctor Payments Data

Jennifer Trickett, APRN

Nurse Practitioner · McHenry, ILNPI 1780338145

Payments from drug & device makers

$1,555in general payments, 2019–2025

Across 48 payments — averaging $32.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$411
  • Regeneron Healthcare Solutions, Inc.$279
  • Boehringer Ingelheim$160
  • Verona Pharma, Inc.$160
  • Electromed, Inc.$158
  • Actelion Pharmaceuticals US, Inc.$122
  • plus $265 from 4 others

What the payments were for

  • Food & beverage$1,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,555 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$48,792
Medicare patients
380
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate31$482,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter469$411,604
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr179$104,411
Stiolto RespimatTiotropium Br/Olodaterol Hcl158$96,825
Dupixent PenDupilumab11$86,018
Pirfenidone50$77,406
Breo ElliptaFluticasone/Vilanterol142$73,354
Spiriva RespimatTiotropium Bromide81$68,320
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$31,726
Incruse ElliptaUmeclidinium Bromide60$31,114
Combivent RespimatIpratropium/Albuterol Sulfate27$18,550
Albuterol Sulfate HfaAlbuterol Sulfate338$11,952
SymbicortBudesonide/Formoterol Fumarate45$11,707
Wixela InhubFluticasone Propion/Salmeterol59$8,832
DuleraMometasone/Formoterol22$8,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$160$666,109297 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$116$50,928106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in McHenry

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →